Article

Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-Aβ antibody

Neuroscience Discovery Research, Eli Lilly and Company, Indianapolis, Indiana 46285, USA.
Journal of Clinical Investigation (Impact Factor: 13.77). 04/2006; 116(3):825-32. DOI: 10.1172/JCI27120
Source: PubMed

ABSTRACT Disruption of cholinergic neurotransmission contributes to the memory impairment that characterizes Alzheimer disease (AD). Since the amyloid cascade hypothesis of AD pathogenesis postulates that amyloid beta (A beta) peptide accumulation in critical brain regions also contributes to memory impairment, we assessed cholinergic function in transgenic mice where the human A beta peptide is overexpressed. We first measured hippocampal acetylcholine (ACh) release in young, freely moving PDAPP mice, a well-characterized transgenic mouse model of AD, and found marked A beta-dependent alterations in both basal and evoked ACh release compared with WT controls. We also found that A beta could directly interact with the high-affinity choline transporter which may impair steady-state and on-demand ACh release. Treatment of PDAPP mice with the anti-A beta antibody m266 rapidly and completely restored hippocampal ACh release and high-affinity choline uptake while greatly reducing impaired habituation learning that is characteristic of these mice. Thus, soluble "cholinotoxic" species of the A beta peptide can directly impair cholinergic neurotransmission in PDAPP mice leading to memory impairment in the absence of overt neurodegeneration. Treatment with certain anti-A beta antibodies may therefore rapidly reverse this cholinergic dysfunction and relieve memory deficits associated with early AD.

Download full-text

Full-text

Available from: Steven M Paul, Sep 01, 2015
0 Followers
 · 
116 Views
 · 
24 Downloads
  • Source
    • "Transplantation of stem cells has shown promise for improving functional recovery for Alzheimer's disease. MSCs could promote survival, increased the metabolic activity and help to rescue the AD cell model in vitro [47]. The coculture of human MSCs and BV-2, mouse microglia, increased neprilysine expression, the Aβ-degrading enzyme, under the exposure of Aβ [48]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The loss of neuronal cells in the central nervous system may occur in many neurodegenerative diseases. Alzheimer's disease is a common senile disease in people over 65 years, and it causes impairment characterized by the decline of mental function, including memory loss and cognitive impairment, and affects the quality of life of patients. However, the current therapeutic strategies against AD are only to relieve symptoms, but not to cure it. Because there are only a few therapeutic strategies against Alzheimer's disease, we need to understand the pathogenesis of this disease. Cell therapy may be a powerful tool for the treatment of Alzheimer's disease. This review will discuss the characteristics of Alzheimer's disease and various available therapeutic strategies.
    03/2014; 23(1):45-52. DOI:10.5607/en.2014.23.1.45
  • Source
    • "AD patients have reduced ACh synthesis and impaired cortical cholinergic function (Whitehouse et al. 1982). This is consistent with animal studies showing that Ab reduces ACh production and release (Kar et al. 2004; Bales et al. 2006). The AChEI act by inhibiting the enzyme AChE which is anchored in the synaptic cleft at cholinergic synapses. "
    [Show abstract] [Hide abstract]
    ABSTRACT: It has become increasingly clear that inflammatory processes play a significant role in the pathophysiology of Alzheimer’s disease (AD). Neuroinflammation is characterized by the activation of astrocytes and microglia and the release of proinflammatory cytokines and chemokines. Vascular inflammation, mediated largely by the products of endothelial activation, is accompanied by the production and the release of a host of inflammatory factors which contribute to vascular, immune, and neuronal dysfunction. The complex interaction of these processes is still only imperfectly understood, yet as the mechanisms continue to be elucidated, targets for intervention are revealed. Although many of the studies to date on therapeutic or preventative strategies for AD have been narrowly focused on single target therapies, there is accumulating evidence to suggest that the most successful treatment strategy will likely incorporate a sequential, multifactorial approach, addressing direct neuronal support, general cardiovascular health, and interruption of deleterious inflammatory pathways.
    Inflammopharmacology 06/2012; 20(3):109-126. DOI:10.1007/s10787-012-0130-z
  • Source
    • "In neuronal culture/in vitro studies, β-amyloid has been shown to reduce high affinity choline uptake, decrease the rate of acetylcholine (ACh) synthesis, inhibit ACh release, and impair muscarinic receptor activation of G proteins [8,36]. Elegant studies by Bales and colleagues produced very direct and compelling evidence for the negative impact of β-amyloid on cholinergic function [38]. These workers measured ACh release within the hippocampus using an in vivo microdialysis technique in awake, moving mice. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The olfactory bulb (OB) receives extensive cholinergic input from the basal forebrain and is affected very early in Alzheimer's disease (AD). We speculated that an olfactory 'stress test' (OST), targeting the OB, might be used to unmask incipient AD. We investigated if change in olfactory performance following intranasal atropine was associated with several known antecedents or biomarkers of AD. We measured change in performance on the University of Pennsylvania Smell Identification Test (UPSIT) in the left nostril before (20-items) and after (remaining 20-items) intranasal administration of 1 mg of atropine. We administered cognitive tests, measured hippocampal volume from MRI scans and recorded Apolipoprotein E genotype as indices relevant to underlying AD. In a convenience sample of 56 elderly individuals (14 probable AD, 13 cognitive impairment no dementia, 29 cognitively intact) the change in UPSIT score after atropine ('atropine effect' = AE) correlated significantly with demographically scaled episodic memory score (r = 0.57, p < 0.001) and left hippocampal volume (LHCV) (r = 0.53, p < 0.001). Among non-demented individuals (n = 42), AE correlated with episodic memory (r = 0.52, p < 0.001) and LHCV (r = 0.49, p < 0.001) and hierarchical linear regression models adjusted for age, gender, education, and baseline UPSIT showed that the AE explained more variance in memory performance (24%) than did LHCV (15%). The presence of any APOE ϵ4 allele was associated with a more negative AE (p = 0.014). The OST using atropine as an olfactory probe holds promise as a simple, inexpensive screen for early and preclinical AD and further work, including longitudinal studies, is needed to explore this possibility.
    BMC Neurology 05/2012; 12:24. DOI:10.1186/1471-2377-12-24 · 2.49 Impact Factor
Show more